The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Nous-209 has been developed using the Nouscom's viral vector platform
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Subscribe To Our Newsletter & Stay Updated
